doi: 10.1016/S0304-3940(01)01618-4 191 PerryTHaugheyNJMattsonMPEganJMGreigNH
GLP-1 agonists can help reduce the risk of cardiovascular events
A far larger share (62%) say these drugs are not good options for people without a weight-related health condition, while 26% arent sure
If the litigation proceeds, bellwether trials could begin in 2027 and will provide insight into how juries respond to these claims
glp-1 market access prior authorization GLP-1 Market Access: PBM Prior Auth & First-Fill Metrics May 5, 2026 45 min read Review 2026 GLP-1 market access metrics, including PBM prior authorization denial rates, turnaround times, and first-fill benchmarks for commercial teams
Clinical studies and meta-analyses have identified an increased risk of gallbladder disease with GLP-1 receptor agonist use, particularly with weight loss medications